TOREMIFENE - PHARMACOLOGIC AND PHARMACOKINETIC BASIS OF REVERSING MULTIDRUG RESISTANCE

被引：84

作者：

DEGREGORIO, MW ^{[1
]}

FORD, JM ^{[1
]}

BENZ, CC ^{[1
]}

WIEBE, VJ ^{[1
]}

机构：

[1] UNIV CALIF SAN FRANCISCO,INST CANC RES,SAN FRANCISCO,CA 94143

来源：

JOURNAL OF CLINICAL ONCOLOGY | 1989年 / 7卷 / 09期

关键词：

D O I：

10.1200/JCO.1989.7.9.1359

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1359 / 1364

页数：6

共 22 条

[1]

CHABNER BA, 1983, CANCER TREAT REP, V67, P855

[2]

CORNWELL MM, 1986, J BIOL CHEM, V261, P7921

[3]

EBBS SR, 1987, LANCET, V2, P621

[4]

FORD JM, 1989, MOL PHARMACOL, V35, P105

[5]

FOSTER BJ, 1988, CANCER CHEMOTH PHARM, V22, P147

[6]

GREENBERG DA, 1987, CANCER RES, V47, P70

[7]

HOLLERAN WM, 1987, ANAL LETT, V20, P871

[8]

INABA M, 1984, JPN J CANCER RES, V75, P1049

[9] TAMOXIFEN IS A CALMODULIN ANTAGONIST IN THE ACTIVATION OF CAMP PHOSPHODIESTERASE [J].

LAM, HYP .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1984, 118 (01) :27-32

[10] CLINICAL MODULATION OF DOXORUBICIN RESISTANCE BY THE CALMODULIN-INHIBITOR, TRIFLUOPERAZINE - A PHASE-I/II TRIAL [J].

MILLER, RL ;

BUKOWSKI, RM ;

BUDD, GT ;

PURVIS, J ;

WEICK, JK ;

SHEPARD, K ;

MIDHA, KK ;

GANAPATHI, R .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (05) :880-888

← 1 2 3 →